Abstract
Purpose: To determine the antiplatelet effect of cilostazol (Pletal®) and its interaction with dipyridamole in in vitro and in vivo rabbit models, and to see if it can be dissociated from bleeding time prolongation.
Methods: In vitro collagen-induced platelet aggregation was measured by an impedance-based aggregometer. The in vivo antithrombotic effect was evaluated in a rabbit carotid artery cyclic flow reduction (CFR) model, in which repetitive thrombosis was induced by mechanical injuries of the artery and stenosis. Template bleeding time was determined in rabbit ear arterioles and hindlimb nail cuticles.
Results: In vitro platelet aggregation was slightly inhibited by 4 μ M cilostazol (22 ± 6%), and modestly by 13 μ M (57 ± 3% of aggregation). While dipyridamole itself up to 13 μ M had no significant inhibition, it potentiated the effect from cilostazol: in the presence of 4 μ M dipyridamole, 4 μ M cilostazol inhibited aggregation by 47 ± 6%. Dipyridamole also potentiated the CFR reducing effect of cilostazol: combination of dipyridamole (no effect by itself) and cilostazol at 1 μ M decreased CFRs to levels achieved by 3–4 μ M cilostazol alone. Bleeding times were similar in controls and animals treated with cilostazol, or with cilostazol and dipyridamole. In contrast, aspirin (4 mg/kg), while reducing CFRs, significantly increased bleeding time.
Conclusion: These results suggest that dipyridamole potentiates the antiplatelet effect of cilostazol without prolongation of the bleeding time, implying a potential novel combination antithrombotic therapy.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Shakur Y, Fong M, Hensley J, et al. Comparison of the effects of cilostazol and milrinone on cAMP-PDE activity, intracellular cAMP and calcium in the heart. Cardiovascular Drugs and Therapy 2002;16:417–427.
Ikeda Y, Sudo T, Kimura Y. Cilostazol. In: Michelson AD, ed. Platelets. Academic Press, 2002:817–823.
Liu Y, Shakur Y, Yoshitake M, et al. Cilostazol (Pletal): A dual inhibitor of cyclic nucleotide phosphodiesterase type 3 and adenosine uptake. Cardiovasc Drug Rev 2001;19:369–386.
Kambayashi J, Liu Y, Sun B, et al. Cilostazol as a unique antithrombotic agent. Curr Pharm Des 2003;9:2289–2308.
Wang S, Cone J, Fong M, et al. Interplay between inhibition of adenosine uptake and phosphodiesterase type 3 on cardiac function by cilostazol, an agent to treat intermittent claudication. J Cardiovasc Pharmacol 2001;38:775–783.
Liu Y, Fong M, Cone J, et al. Inhibition of adenosine uptake and augmentation of ischemia-induced increase of interstitial adenosine by cilostazol, an agent to treat intermittent claudication. J Cardiovasc Pharmacol 2000;36:351–360.
Sun B, Le SN, Lin S, et al. New mechanism of action for cilostazol: Interplay between adenosine and cilostazol in inhibiting platelet activation. J Cardiovasc Pharmacol 2002;40:577–585.
Cone J, Wang S, Tandon N, et al. Comparison of the effects of cilostazol and milrinone on intracellular cAMP levels and cellular function in platelets and cardiac cells. J Cardiovasc Pharmacol 1999;34:497–504.
Liu Y, Cone J, Le SN, et al. Cilostazol and dipyridamole synergistically inhibit human platelet aggregation. J Cardiovasc Pharmacol 2004;44:266–273.
Folts J. An in vivo model of experimental arterial stenosis, intimal damage, and periodic thrombosis. Circulation 1991;83:IV3–IV14.
Bush LR, Shebuski RJ. in vivo models of arterial thrombosis and thrombolysis. FASEB J 1990;4:3087–3098.
Kim JS, Lee KS, Kim YI, et al. A randomized crossover comparative study of aspirin, cilostazol and clopidogrel in normal controls: Analysis with quantitative bleeding time and platelet aggregation test. J Clin Neurosci 2004;11:600–602.
Mallikaarjun S, Forbes WP, Bramer SL. Interaction potential and tolerability of the coadministration of cilostazol and aspirin. Clin Pharmacokinet 1999;37(Suppl 2):87–93.
Wilhite DB, Comerota AJ, Schmieder FA, et al. Managing PAD with multiple platelet inhibitors: The effect of combination therapy on bleeding time. J Vasc Surg 2003;38:710–713.
Diener HC, Cunha L, Forbes C, et al. European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 1996;143:1–13.
Fu CJ, Tata PN, Okada K, et al. Simultaneous quantitative determination of cilostazol and its metabolites in human plasma by high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl 1999;728:251–262.
Marret E, Bonnin P, Mazoyer E, et al. The effects of a polymerized bovine-derived hemoglobin solution in a rabbit model of arterial thrombosis and bleeding. Anesth Analg 2004;98:604–610.
Sudo T, Ito H, Ozeki Y, et al. Estimation of anti-platelet drugs on human platelet aggregation with a novel whole blood aggregometer by a screen filtration pressure method. Br J Pharmacol 2001;133:1396–1404.
Kariyazono H, Nakamura K, Arima J, et al. Evaluation of anti-platelet aggregatory effects of aspirin, cilostazol and ramatroban on platelet-rich plasma and whole blood. Blood Coagul Fibrinolysis 2004;15:157–167.
Igawa T, Tani T, Chijiwa T, et al. Potentiation of anti-platelet aggregating activity of cilostazol with vascular endothelial cells. Thromb Res 1990;57:617–623.
Bramer SL, Forbes WP, Mallikaarjun S. Cilostazol pharmacokinetics after single and multiple oral doses in healthy males and patients with intermittent claudication resulting from peripheral arterial disease. Clin Pharmacokinet 1999;37 (Suppl 2):1–11.
Beebe HG, Dawson DL, Cutler BS, et al. A new pharmacological treatment for intermittent claudication: Results of a randomized, multicenter trial. Arch Intern Med 1999;159:2041–2050.
Tamai Y, Takami H, Nakahata R, et al. Comparison of the effects of acetylsalicylic acid, ticlopidine and cilostazol on primary hemostasis using a quantitative bleeding time test apparatus. Haemostasis 1999;29:269–276.
Tijssen JG. Low-dose and high-dose acetylsalicylic acid, with and without dipyridamole: A review of clinical trial results. Neurology 1998;51:S15–S16.
Schmidt U, Han RO, DiSalvo TG, et al. Cessation of platelet-mediated cyclic canine coronary occlusion after thrombolysis by combining nitric oxide inhalation with phosphodiesterase-5 inhibition. J Am Coll Cardiol 2001;37:1981–1988.
Herbert JM, Dol F, Bernat A, et al. The antiaggregating and antithrombotic activity of clopidogrel is potentiated by aspirin in several experimental models in the rabbit. Thromb Haemost 1998;80:512–518.
Elg M, Carlsson S, Gustafsson D. Effects of agents, used to treat bleeding disorders, on bleeding time prolonged by a very high dose of a direct thrombin inhibitor in anesthesized rats and rabbits. Thromb Res 2001;101:159– 170.
Himber J, Kirchhofer D, Riederer M, et al. Dissociation of antithrombotic effect and bleeding time prolongation in rabbits by inhibiting tissue factor function. Thromb Haemost 1997;78:1142–1149.
Nomura S, Inami N, Iwasaka T, et al. Platelet activation markers, microparticles and soluble adhesion molecules are elevated in patients with arteriosclerosis obliterans: Therapeutic effects by cilostazol and potentiation by dipyridamole. Platelets 2004;15:167–172.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Li, H., Cone, J., Fong, M. et al. Antiplatelet and Antithrombotic Activity of Cilostazol is Potentiated by Dipyridamole in Rabbits and Dissociated from Bleeding Time Prolongation. Cardiovasc Drugs Ther 19, 41–48 (2005). https://doi.org/10.1007/s10557-005-6896-0
Issue Date:
DOI: https://doi.org/10.1007/s10557-005-6896-0